CA2086566A1 - Inhibitor for absorption of digested and decomposed products of food and drink - Google Patents
Inhibitor for absorption of digested and decomposed products of food and drinkInfo
- Publication number
- CA2086566A1 CA2086566A1 CA002086566A CA2086566A CA2086566A1 CA 2086566 A1 CA2086566 A1 CA 2086566A1 CA 002086566 A CA002086566 A CA 002086566A CA 2086566 A CA2086566 A CA 2086566A CA 2086566 A1 CA2086566 A1 CA 2086566A1
- Authority
- CA
- Canada
- Prior art keywords
- drink
- food
- digested
- absorption
- decomposed products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 40
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 22
- 239000003112 inhibitor Substances 0.000 title claims abstract description 11
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 25
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 24
- 230000002378 acidificating effect Effects 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 235000020971 citrus fruits Nutrition 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000002265 prevention Effects 0.000 abstract description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 5
- 206010010774 Constipation Diseases 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000019647 acidic taste Nutrition 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000000701 coagulant Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 210000001630 jejunum Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 3
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000001112 coagulating effect Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
INHIBITOR FOR ABSORPTION OF DIGESTED AND
DECOMPOSED PRODUCTS OF FOOD AND DRINK
ABSTRACT OF THE DISCLOSURE:
The invention provides an inhibitor for absorption of digested and decomposed products of food and drink, which may be taken at means as a drink. The inhibitor comprises an acidic aqueous solution containing sodium polyacrylate.
It is useful for prevention of fatness, palliation of hyperlipemia, palliation of diabetes, prevention of constipation and palliation of hypohepatia.
DECOMPOSED PRODUCTS OF FOOD AND DRINK
ABSTRACT OF THE DISCLOSURE:
The invention provides an inhibitor for absorption of digested and decomposed products of food and drink, which may be taken at means as a drink. The inhibitor comprises an acidic aqueous solution containing sodium polyacrylate.
It is useful for prevention of fatness, palliation of hyperlipemia, palliation of diabetes, prevention of constipation and palliation of hypohepatia.
Description
., G ~
INHIBITOR FOR ABSORPTION O~ DICESTED t~ND
DECOMPOSED PRODUCTS OF ~OOD AND DRII~K
BACKGROUND OF THE INVENTION:
Field of the Invention S The present invention relates to an inhibitor for absorption of digested and decomposed products of food and drink, which is useful for prevention of fatness, palliation of hyperlipemia, palliation of diabetes, prevention of constipation and palliation of hypohepatia. The "digested and decomposed products of food and drink" as referred to herein include not only nutriments of direct products by digestion and decomposition of food and drink but also metabolites of indirect products by the same.
Prior Art Except the past food-shortage days of our country or the countries of still now suffering from starvation, the harmful effects due to superingestion of nutriments have always involved difficult problems which could hardly be solved by people. Needless to say, theY causes various problems for health and beauty of people. This is because, ~ although anyone could understand the problems on the desk, - ~ the most simple and sure diet could not be carried out easily. The troublesome conditions to be caused by superingestion of nutriments include various adult diseases such as fatness, hyperlipemia, arteriosclerosis, cardiac disorders and diabetes, as well as hypohepatia.
.: ~: :
:
1:
:- - : . . ', ' :
.. .
. . . . -.
' ' '' . : :
.
INHIBITOR FOR ABSORPTION O~ DICESTED t~ND
DECOMPOSED PRODUCTS OF ~OOD AND DRII~K
BACKGROUND OF THE INVENTION:
Field of the Invention S The present invention relates to an inhibitor for absorption of digested and decomposed products of food and drink, which is useful for prevention of fatness, palliation of hyperlipemia, palliation of diabetes, prevention of constipation and palliation of hypohepatia. The "digested and decomposed products of food and drink" as referred to herein include not only nutriments of direct products by digestion and decomposition of food and drink but also metabolites of indirect products by the same.
Prior Art Except the past food-shortage days of our country or the countries of still now suffering from starvation, the harmful effects due to superingestion of nutriments have always involved difficult problems which could hardly be solved by people. Needless to say, theY causes various problems for health and beauty of people. This is because, ~ although anyone could understand the problems on the desk, - ~ the most simple and sure diet could not be carried out easily. The troublesome conditions to be caused by superingestion of nutriments include various adult diseases such as fatness, hyperlipemia, arteriosclerosis, cardiac disorders and diabetes, as well as hypohepatia.
.: ~: :
:
1:
:- - : . . ', ' :
.. .
. . . . -.
' ' '' . : :
.
2 ~ 6 Accordingly, various and uncountable means have heretofore been proposed and carrled out as felk medicine (mostly for the purpose of prevention o~ fatness o~ women).
Various services for prevention of fatness have actually been commercialized. However, in the applicant's experiences, any means for sure, safe and effective prevention of fatness which may be carried and with ease is unknown up to the present.
On the other hand, from the medical viewpoint, various medicines have been sold commerciallY in the West, such as anfetamin, fenfuramin, faseolamin and madindol.
However, all of them act directly or indirectly on the feeding center or the satiety center in the hYpothalamus of the brain. Accordingly, they often involve various harmful side effects such as habituation, hyperpsychosis, sleeplessness and hydrodipsia. The potency of them often ~: lowers due to continuous taking.
In order to overcome the problems, the present inventor has already proposed a coagulant, for example, a means of inhibiting absorption o* digested and decomposed products of food and drink, which comprises sodium polyacrylate pills coated with an aqueous enteric coating film (Japanese Patent Application Laid-Open No. 3-120227).
These form flocs of digested and decomposed products 25~ Of food and drink in intestines due to the coagulating and crosslinking effect of them, whereby the enteric absorption of the products is inhibited, and these are characterized . .
:
~, ,, ~ . . . . .
2 ~ v ~
Various services for prevention of fatness have actually been commercialized. However, in the applicant's experiences, any means for sure, safe and effective prevention of fatness which may be carried and with ease is unknown up to the present.
On the other hand, from the medical viewpoint, various medicines have been sold commerciallY in the West, such as anfetamin, fenfuramin, faseolamin and madindol.
However, all of them act directly or indirectly on the feeding center or the satiety center in the hYpothalamus of the brain. Accordingly, they often involve various harmful side effects such as habituation, hyperpsychosis, sleeplessness and hydrodipsia. The potency of them often ~: lowers due to continuous taking.
In order to overcome the problems, the present inventor has already proposed a coagulant, for example, a means of inhibiting absorption o* digested and decomposed products of food and drink, which comprises sodium polyacrylate pills coated with an aqueous enteric coating film (Japanese Patent Application Laid-Open No. 3-120227).
These form flocs of digested and decomposed products 25~ Of food and drink in intestines due to the coagulating and crosslinking effect of them, whereby the enteric absorption of the products is inhibited, and these are characterized . .
:
~, ,, ~ . . . . .
2 ~ v ~
in that the effect is extremely noticeable and the safety is high.
As everything is so, the best daily life style is such that the daily routine may naturally be per-formed in one's natural daily life. This is because, if anyone make up one's mind to do anything with particular preparedness, he(she) would often fail in it, as so said that anyone is often to be a person who cannot stick to anyone particular.
The same shall apply to the use of the preceding means of inhibiting absorption of digested and decomposed products of food and drink, and the means is desired to be such that anyone may naturally take it in one's daily dietary habits.
The general form of the means of satisfYing the request is a form like a healthy drink, or that is, the means is in the form of a "drinkable formulation." If the means is in the form of granules or tablets, such would involve an image of a medicine, willy-nilly, so that the intake of them in the public or at meals would be difficult. Apart from the outward appearance of them, it is actually impossible to take such granules or tablets into a mouth along with food to crunch them therein. As a result, they would have to be ~' taken after the meal. In particular, when one takes a meal along with other persons, he(she) would often forget to take the means of such granules or tablets later on.
If the means is in the form of a drinkable formulation, it would be free ~rom the problems. This is.
because, the means of such a drinkable formulation may easily ; ..
:: ~
, ,' .
. . . ' ~ : ~ ~ .
As everything is so, the best daily life style is such that the daily routine may naturally be per-formed in one's natural daily life. This is because, if anyone make up one's mind to do anything with particular preparedness, he(she) would often fail in it, as so said that anyone is often to be a person who cannot stick to anyone particular.
The same shall apply to the use of the preceding means of inhibiting absorption of digested and decomposed products of food and drink, and the means is desired to be such that anyone may naturally take it in one's daily dietary habits.
The general form of the means of satisfYing the request is a form like a healthy drink, or that is, the means is in the form of a "drinkable formulation." If the means is in the form of granules or tablets, such would involve an image of a medicine, willy-nilly, so that the intake of them in the public or at meals would be difficult. Apart from the outward appearance of them, it is actually impossible to take such granules or tablets into a mouth along with food to crunch them therein. As a result, they would have to be ~' taken after the meal. In particular, when one takes a meal along with other persons, he(she) would often forget to take the means of such granules or tablets later on.
If the means is in the form of a drinkable formulation, it would be free ~rom the problems. This is.
because, the means of such a drinkable formulation may easily ; ..
:: ~
, ,' .
. . . ' ~ : ~ ~ .
be taken at meals, as if one takes water, soup, tea, beer, Juice or the like, However, the conventional coagulant, especlallY sodium polyacrylate which is a preferred coagulant displaYs a strong viscosity even when a small amount of it is added to water, as is obvious from the fact that addition of it to food as a tackifier is admitted. Therefore, when the coagulant of sodium polyacrylate is directly put in the mouth; then it adheres to everywhere in the mouth to give an extremely unpleasant feeling. The unpleasant feeling is drastic and often lasts for a long period of time (generally, about one hour), Because of the reasons, it has heretofore been impossible to realize a means of inhibiting absorption of digested and decomposed products of food and drink as a drinkable form, SUMMARY OF THE INVENTION:
Under further investigation of the problems, the present invention has been made so as to further elevate and lmprove the effect of the means, The object of the present invention is therefore to provide a means of lnhibiti~ng absorption of digested and decomposed products of food and drink which may be drunk even at means as a drink and also to provide a means of inhibiting fatness. a means of palliating hyperlipemia, a means of palliating diabetes, :~: :
a means of preventing constipation and a means o~ palliating hypohepatia.
~. .
In order to a~tain the preceding ob~ect, the means of the present inventlon of inhibiting absorption of digested and deco~posed products of food and drink is characterized by containing sodium polyacrylate in an acidic aqueous liquid as an active ingredient.
BRIEF EXPL~NATION_OF THE DRAWINGS:
~ ig. 1 is a linear drawin~ to show the variation o~
the serum leucine aminopeptidase due to intake of the drlnk means of the present invention.
10 Fig. 2 is a linear drawing to show the variation of the serum choline esterase due to intake o~ the drink means o~ the present invention.
Fig. 3 is a linear drawing to show the variation o~
the serum triglyceride due to intake o~ the drink means o~
the present invention.
Fig. 4 is a linear drawing to show the variation of the total serum cholesterol due to intake of the drink means of the present invention.
Fig. 5 is a linear drawing to show the variation of the serum beta-lipoprotein due to intake of the drink means of the present invention.
DETAI~ED D~SCRIPTION OF THE INVENTION:
The acidic aqueous liquid of the present invention may be anyone which is acidic and which is drinkable by :~ 25 human beings and animals. It may be one to be prepared by dissolving any particular chemical or industrial products in water or may also be an acidic one which is used as food or drink.
:: ~
- : :
" ~", ' ` ' `' ' ' .
- 6 - 2~ 66 For instance, generally mentioned are an aqueous solution of ascorblc acid, cltric acid, acetic acid or the like, a diluted solution o~ edible vinegar o~ various kinds, and juices of citrus -fruits of lemon, orange and the like.
The acidity of the liquid is to have a pH of 5 or less, preferably from 2.5 to ~.5. Where it has the determined acidity, from 2 to 3 g of sodium polyacrYlate may dissolve in 100 ml of the acidic solution to still maintain à sufficient fluidity for drink. In the case, the resulting solution may have a viscosity of approximately from 0.3 to 0.6 polse, as measured with a viscometer.
The intake may be approximately from 0.05 to 0.1 g/day/adult to generally display the effect. Therefore, when the solution has a concentration of from 2 to 3 g/100 ml, then the intake of only from 1.7 to 5.0 ml/daY is sufficient.
The stock solution may further be diluted for drinkin~.
As mentioned above, a drinkable means suitable as an ordinary drink ls realized by the present invention.
Actual performance of the present invention includes ~;~ 20 two types, one being to take a small amount of the solution of havlng such a high concentration and the other being to take a~satisfactory large amount of a diluted solution having a lowered concentration. As a further developed and preferred drinkable embodiment of the present invention, also employable is a form of a toned drink, such as a honey lemon drink or the like, which is drinkable as it is.
, ~ :
:: : :
' .:
. '~.' ' ' ~ :
..
.
2 ~ 3 ~ 6 For instance, as shown In the -following example, employable is an a~ueous solution contalning 1000 mg of ascorbic acid per 100 ml of water. The solution of the case has a pH value of about 2.8 and gives a somewhat acidic taste. Addition of some sweetness thereto is especially preferred, as giving a refreshing taste like a so-called sports drink.
Needless to say, the gastric liquid is acidic.
Therefore, after drunk, the drink means of the present invention maintains the acidic condition, like that before drunk, still in the inside of the stomach, especially in the gastric first region and second region (the cardiac part and body part of stomach). The sodium polyacrylate of the means is therefore dispersed in and blended with the food in the stomach as a solution thereof.
As previously mentioned, the present inventor has already developed various means of inhibiting digested and decomposed products of food and drink, prior to the present invention, by coating a coagulant such as sodium polyacrylate or the like with an aqueous enteric coating . ~ .
film or by encapsulating it into enteric capsules in order that the enteric coated granules, pills or capsules (hard capsules or soft capsules) may be dispersed in and blended ~; wIth the food in the stomach after administered.
Being dlfferent from the previously developed means, the drink me:ans of the present invention already contains sodium polyacrylate in an aqueous liquid before it is drunk, and the aqueous liquid condition of the means is stil.l . - . :: - . , . . .. , . -: . ~ . , . : . . , .. , - - , : :. ~ .
:. ... . . . . :, . - : . . : .
.. . .
.: . , : : .:
maintained also in the stomach, after drunk, with it being blended with and dispersed in the food and drink in the stomach, whereupon the sodium polyacrylate is then petrissa~e into the details of the food due to the strong petrified action of the stomach to the result that the coagulating effect of the sodium polyacrylate is elevated further more.
As a result, when the same intake of the means of the present invention as that of the means of the prior art is taken, the effect of the former is larger than the latter. Accordingly, if the effect of the same degree is intended to be attained, the intake of the drink means of the present invention may be reduced much.
Though not considered due to only the effect in the stomach, the drink means of the present invention has been lS found to attain almost the same effect in the intake of approximately from 1/10 to 1/40 of the preceding conventional means of inhibiting absorption of digested and decomposed products of food and drink.
Digestion and decomposition of food further progress from the gastric third region (pylorus area) to the upper region of the small intestine (from duodenum to jejunum) in such a way that the food is digested and decomposed to the molecules and simultaneously absorbed. In the said regions and the subsequent regions, the digested and ~; 25 decomposed products of food and drink are coagulated by ~ sodium polyacrylate. Since sodium polYacrylate has alreadY
;~ been dispersed in the digested and decomposed products of ~ food and drink as a solution thereof, in taking the drink :
. :. .
. . . : .
. "' " ' . :
- . . ' . . ~ ' ' ' . .
` . ' " ' ' 2 V ) iJI ~ U ~
means of the present invention, formation of coa~ulated ~locs of the digested and decomposed products of ~ood and drink is effected more efficiently.
When the conventional means of inhibiting absorption o~ the digested and decomposed products of food and drink is taken, then the aqueous gastric coating film of coating the active ingredient of sodium polyacrylate is dissolved in the area of from the gastric third region to the upper region of the small intestine so that the liberated active ingredient may coagulate the digested and decomposed products of food and drink in the subsequent area after the regions.
However, the active ingredient of sodium polyacrylate itself would often form large solid masses in the stomach to hardly attain the necessary dispersion and admixture of it with the food and, as a result, formation of sufficient food flocs is often impossible to lower the effect of the ingredient. The reason may be presumed because water would penetrate into the liberated pills or granules, after the aqueous enteric coating film of coating them has been dissolved but before the pills or granules could sufficiently be dispersed, to give coagulated masses essentially composed of sodium polyacrylate and, as a result, the non-dispersed masses would directly pass through the intestinal tubes as they are.
Anyhow, since the drink means of the present invention is in the form of a liquid and additionally the liquid may maintain the acidic cond~tion still in the stomach of displaying a high stirring activity, it may ~e dispersed in and blended with even the details of food and drink and also .. . ~
2S~G~
those o~ the digested and decomposed products of them much more than the conventional means and, as a result, it may display much more elevated coagulating effect and absorption-inhibiting effect than the latter.
The coagulate forms masses and flocs essentially due to the crosslinking between the digested and decomposed products of food and drink and sodium polyacrylate and the surfaces of the masses and flocs are pasty or puipy (like molten potato starch). Accordingly, the coagulate of the form is prevented from being absorbed from the walls of the intestines, when it moves small intestines, especlally ln the jejunum which is the essential site of absorbing it. As a result, absorption of the digested and decomposed products of food and drink as taken into a body may be inhibited in the determined amount corresponding to the amount of the drink means of the present invention as also taken into the same, while they are discharged out of the body as feces.
The coagulate includes various products (nutriments) resulting from digestion and decomposition of food and drink, 20~ such as lipids, hydrocarbon and others. AccordinglY, the drink means of the present invention of inhibiting absorption of them acts also as a means of preventing fatness.
Since the surface of the coagulate is pasty or pulpy (llke molten potato starch) and such is blended in the food 25 ~ residue or feces, the resulting blend may smoothly pass :
through the intestines. Therefore, it does not cause disorder of the membranes of the lntestinal walls but it rather obviously displays an effect of promoting the : ~:
. . . .
- - , ' '~ ' -, ,:
- ... : . ,,., , :
evacuation of the bowels so that it is also e~fective as a means of preventing constipation.
From the test results of the following example, the drink means of the present invention is noted to also display the effect of palliating hypohepatia, in view of the indices of the blood lipids as well as the leucine aminopeptidase.
choline esterase and others. From them, the drink means of the present invention is expected to be also e~fective as a means of palliating hypohepatia.
The drink means of the present invention may be blended with dietary fibers, chitin, chitosan and others, whereby the effects of it may be improved further.
As explained in the above, the drink means of the present invention contains sodium polyacrylate, as an active ingredient, in an acidic aqueous liquid and display the same property as ordinary drinks. Therefore, belng different from the conventional means, it may be taken at meals light-heartedly with ease.
As being a liquid, the drink means of the present invention may well be penetrated and dispersed into the details of food in the stomach to the result that it may display the same effect as the conventional means even when taken in a much smaller amount than the latter.
To prepare the conventional means, coating of an aqueous enteric coating film over powder or granules :: `
of sodium polyacrylate is necessary. However, such coating is very complicated. For instance, a material of the aqueous enteric Foating film, such as hYdroxYProPYlmethyl cellulose :
.
`' ~ - ' - ' '' ' :, ' '. ' -- . .
2~Gti~S
acetate succinate, may be dissolved only ln a highly inflammable and toxic solvent such as acetone; and the material is sprayed and dried over granules of sodium polyacrylate. Such treatment needs much expensive facilities and manY steps to the result that the cost of the coated granules is inevitably high.
Contrary to this, the drink means of the present invention may well be prepared only by adding sodium polyacrYlate into an acidic aqueous liquid followed by blending them. Thus, it may be prepared extremelY easily at a low cost.
Next, the present invention will be explained in more detail by way of the following examples, which, however, are not intended to restrict the scope of the present invention.
EXAMPLE
Pre~aration of Drink Means:
1000 mg of ascorbic acid was dissolved in 100 ml of a so-called sports drink-like toned aqueous liquid as prepared by adding an electrolyte to water along with some flavorings, to yield an acidic aqueous liquid. This had an aciditY of pH 2.8 and gave an acidic taste.
0.05 g of sodium polyacrylate was dissolved in 100 ml of the liquid to prepare a drink means.
Before and after addition of sodium polyacrylate, the liquid had no noticeable change in the viscosity and the fluidity. (The viscosity was about 0.02 poise a-t 20~C.) ~ .
' '' , ' , ~3(jv~
Test of_Drlnk Means:
The conditions of testing the drink means thus prepared are as follows:
- 14 - ~ J J ~ ~
a~
o a~
J ~
C~ O O O 9 O ~ _ o O ~ ~ p, ~, ~, p, O O o~
O O O O O O
S
O
~1 ~11~ 5 ~ ~ ~1 ~
C~ O O O O O O
~
O q~
C~ O
~1 ~
,~ _ ~:: Ot--111 N ~ u) ~ . . . .
O ~
S--~0 ~ OCO OC`~ O C~
O ~~1 ~ ~I Q) ~( X ~ 0 ~ 0 ~
e ~
c~ v U~ tO
q~
U~ O U~
--I ¢o~ C) ~ r~
C~
o h 1~ t ~i Test Period: Four months from July to October, 1991 How to take the drink means:
They took lOO ml of the drink means each at their lunch and supper meals (corresponding to about 0.1 g/day of-sodium polyacrylate).
The contents of their meals were not specifically defined and they continued their own ordinarY dietary habits during the test.
How to obtain the test data:
All the panelists were subjected to general blood examination and biochemical examination of about 40 items, before the test and at every one month after initiation of the test, whereupon the variation of the condition of each of them was checked continuously.
From the test results, noticeable depression of the leucine aminopeptidase, choline esterase, triglyceride, whole cholesterol and beta-lipoprotein in the serum was admitted in all the panelists. The test data are shown in Fig. 1 to Fig. 5, in which each line graph indicates the variation of the tested item of each panelist tested. As is noted therefrom, depresslon of all the tested components in the serum is significant in every panelist. Thus. the effect of taking the drink means was demonstrated by the test.
Naturally, the total cholesterol is to gradually lower in three~months to a half year or to one year. In the present test, depression of the value was obvious in four (A, B, D, F) of all the six panelists. The effect of the drlnk means was veriiied also in this point.
~:
' . .
:, .
t~
The variation of the weigh~ of each panellst was as follows:
Variation of Weight:
During the test, the condition of each panelist of evacuating the bowels (the number of evacuating the bowels, the amount of the discharged feces, the appearance of the discharged feces, and the condition in evacuating the bowels, etc.) as well as the variation of the subjective symptoms of each panelist during the test period of four months of taking the drink means of the example were recorded every day. Before the test, all the panelists were in the habit of being constipated. From 3 days to one week after initiation of the test of taking the drink means, all became to evacuate the bowels once to three times a day. Both the solidness of lS the discharged feces and the condition thereof were good.
In addition, it was also observed that the color of the discharged feces changed to a clear bile color in every panelist. This means that the drink means of the present invention coagulated the bile and bile acid in the tested panelist to discharge them out of the body. Bile acid is formed essentially from the blood lipids and is again absorbed in the jejunum. Due to inhibition of the absorption of the bile acid in the jejunum, the metabolism of fats in the body is thereby promoted. In this point, the drink means of the present invention is noted to have still other effects of palliating hyperlipemia and of palliating hypohepatia.
Under further investigation of the problems, the present invention has been made so as to further elevate and lmprove the effect of the means, The object of the present invention is therefore to provide a means of lnhibiti~ng absorption of digested and decomposed products of food and drink which may be drunk even at means as a drink and also to provide a means of inhibiting fatness. a means of palliating hyperlipemia, a means of palliating diabetes, :~: :
a means of preventing constipation and a means o~ palliating hypohepatia.
~. .
In order to a~tain the preceding ob~ect, the means of the present inventlon of inhibiting absorption of digested and deco~posed products of food and drink is characterized by containing sodium polyacrylate in an acidic aqueous liquid as an active ingredient.
BRIEF EXPL~NATION_OF THE DRAWINGS:
~ ig. 1 is a linear drawin~ to show the variation o~
the serum leucine aminopeptidase due to intake of the drlnk means of the present invention.
10 Fig. 2 is a linear drawing to show the variation of the serum choline esterase due to intake o~ the drink means o~ the present invention.
Fig. 3 is a linear drawing to show the variation o~
the serum triglyceride due to intake o~ the drink means o~
the present invention.
Fig. 4 is a linear drawing to show the variation of the total serum cholesterol due to intake of the drink means of the present invention.
Fig. 5 is a linear drawing to show the variation of the serum beta-lipoprotein due to intake of the drink means of the present invention.
DETAI~ED D~SCRIPTION OF THE INVENTION:
The acidic aqueous liquid of the present invention may be anyone which is acidic and which is drinkable by :~ 25 human beings and animals. It may be one to be prepared by dissolving any particular chemical or industrial products in water or may also be an acidic one which is used as food or drink.
:: ~
- : :
" ~", ' ` ' `' ' ' .
- 6 - 2~ 66 For instance, generally mentioned are an aqueous solution of ascorblc acid, cltric acid, acetic acid or the like, a diluted solution o~ edible vinegar o~ various kinds, and juices of citrus -fruits of lemon, orange and the like.
The acidity of the liquid is to have a pH of 5 or less, preferably from 2.5 to ~.5. Where it has the determined acidity, from 2 to 3 g of sodium polyacrYlate may dissolve in 100 ml of the acidic solution to still maintain à sufficient fluidity for drink. In the case, the resulting solution may have a viscosity of approximately from 0.3 to 0.6 polse, as measured with a viscometer.
The intake may be approximately from 0.05 to 0.1 g/day/adult to generally display the effect. Therefore, when the solution has a concentration of from 2 to 3 g/100 ml, then the intake of only from 1.7 to 5.0 ml/daY is sufficient.
The stock solution may further be diluted for drinkin~.
As mentioned above, a drinkable means suitable as an ordinary drink ls realized by the present invention.
Actual performance of the present invention includes ~;~ 20 two types, one being to take a small amount of the solution of havlng such a high concentration and the other being to take a~satisfactory large amount of a diluted solution having a lowered concentration. As a further developed and preferred drinkable embodiment of the present invention, also employable is a form of a toned drink, such as a honey lemon drink or the like, which is drinkable as it is.
, ~ :
:: : :
' .:
. '~.' ' ' ~ :
..
.
2 ~ 3 ~ 6 For instance, as shown In the -following example, employable is an a~ueous solution contalning 1000 mg of ascorbic acid per 100 ml of water. The solution of the case has a pH value of about 2.8 and gives a somewhat acidic taste. Addition of some sweetness thereto is especially preferred, as giving a refreshing taste like a so-called sports drink.
Needless to say, the gastric liquid is acidic.
Therefore, after drunk, the drink means of the present invention maintains the acidic condition, like that before drunk, still in the inside of the stomach, especially in the gastric first region and second region (the cardiac part and body part of stomach). The sodium polyacrylate of the means is therefore dispersed in and blended with the food in the stomach as a solution thereof.
As previously mentioned, the present inventor has already developed various means of inhibiting digested and decomposed products of food and drink, prior to the present invention, by coating a coagulant such as sodium polyacrylate or the like with an aqueous enteric coating . ~ .
film or by encapsulating it into enteric capsules in order that the enteric coated granules, pills or capsules (hard capsules or soft capsules) may be dispersed in and blended ~; wIth the food in the stomach after administered.
Being dlfferent from the previously developed means, the drink me:ans of the present invention already contains sodium polyacrylate in an aqueous liquid before it is drunk, and the aqueous liquid condition of the means is stil.l . - . :: - . , . . .. , . -: . ~ . , . : . . , .. , - - , : :. ~ .
:. ... . . . . :, . - : . . : .
.. . .
.: . , : : .:
maintained also in the stomach, after drunk, with it being blended with and dispersed in the food and drink in the stomach, whereupon the sodium polyacrylate is then petrissa~e into the details of the food due to the strong petrified action of the stomach to the result that the coagulating effect of the sodium polyacrylate is elevated further more.
As a result, when the same intake of the means of the present invention as that of the means of the prior art is taken, the effect of the former is larger than the latter. Accordingly, if the effect of the same degree is intended to be attained, the intake of the drink means of the present invention may be reduced much.
Though not considered due to only the effect in the stomach, the drink means of the present invention has been lS found to attain almost the same effect in the intake of approximately from 1/10 to 1/40 of the preceding conventional means of inhibiting absorption of digested and decomposed products of food and drink.
Digestion and decomposition of food further progress from the gastric third region (pylorus area) to the upper region of the small intestine (from duodenum to jejunum) in such a way that the food is digested and decomposed to the molecules and simultaneously absorbed. In the said regions and the subsequent regions, the digested and ~; 25 decomposed products of food and drink are coagulated by ~ sodium polyacrylate. Since sodium polYacrylate has alreadY
;~ been dispersed in the digested and decomposed products of ~ food and drink as a solution thereof, in taking the drink :
. :. .
. . . : .
. "' " ' . :
- . . ' . . ~ ' ' ' . .
` . ' " ' ' 2 V ) iJI ~ U ~
means of the present invention, formation of coa~ulated ~locs of the digested and decomposed products of ~ood and drink is effected more efficiently.
When the conventional means of inhibiting absorption o~ the digested and decomposed products of food and drink is taken, then the aqueous gastric coating film of coating the active ingredient of sodium polyacrylate is dissolved in the area of from the gastric third region to the upper region of the small intestine so that the liberated active ingredient may coagulate the digested and decomposed products of food and drink in the subsequent area after the regions.
However, the active ingredient of sodium polyacrylate itself would often form large solid masses in the stomach to hardly attain the necessary dispersion and admixture of it with the food and, as a result, formation of sufficient food flocs is often impossible to lower the effect of the ingredient. The reason may be presumed because water would penetrate into the liberated pills or granules, after the aqueous enteric coating film of coating them has been dissolved but before the pills or granules could sufficiently be dispersed, to give coagulated masses essentially composed of sodium polyacrylate and, as a result, the non-dispersed masses would directly pass through the intestinal tubes as they are.
Anyhow, since the drink means of the present invention is in the form of a liquid and additionally the liquid may maintain the acidic cond~tion still in the stomach of displaying a high stirring activity, it may ~e dispersed in and blended with even the details of food and drink and also .. . ~
2S~G~
those o~ the digested and decomposed products of them much more than the conventional means and, as a result, it may display much more elevated coagulating effect and absorption-inhibiting effect than the latter.
The coagulate forms masses and flocs essentially due to the crosslinking between the digested and decomposed products of food and drink and sodium polyacrylate and the surfaces of the masses and flocs are pasty or puipy (like molten potato starch). Accordingly, the coagulate of the form is prevented from being absorbed from the walls of the intestines, when it moves small intestines, especlally ln the jejunum which is the essential site of absorbing it. As a result, absorption of the digested and decomposed products of food and drink as taken into a body may be inhibited in the determined amount corresponding to the amount of the drink means of the present invention as also taken into the same, while they are discharged out of the body as feces.
The coagulate includes various products (nutriments) resulting from digestion and decomposition of food and drink, 20~ such as lipids, hydrocarbon and others. AccordinglY, the drink means of the present invention of inhibiting absorption of them acts also as a means of preventing fatness.
Since the surface of the coagulate is pasty or pulpy (llke molten potato starch) and such is blended in the food 25 ~ residue or feces, the resulting blend may smoothly pass :
through the intestines. Therefore, it does not cause disorder of the membranes of the lntestinal walls but it rather obviously displays an effect of promoting the : ~:
. . . .
- - , ' '~ ' -, ,:
- ... : . ,,., , :
evacuation of the bowels so that it is also e~fective as a means of preventing constipation.
From the test results of the following example, the drink means of the present invention is noted to also display the effect of palliating hypohepatia, in view of the indices of the blood lipids as well as the leucine aminopeptidase.
choline esterase and others. From them, the drink means of the present invention is expected to be also e~fective as a means of palliating hypohepatia.
The drink means of the present invention may be blended with dietary fibers, chitin, chitosan and others, whereby the effects of it may be improved further.
As explained in the above, the drink means of the present invention contains sodium polyacrylate, as an active ingredient, in an acidic aqueous liquid and display the same property as ordinary drinks. Therefore, belng different from the conventional means, it may be taken at meals light-heartedly with ease.
As being a liquid, the drink means of the present invention may well be penetrated and dispersed into the details of food in the stomach to the result that it may display the same effect as the conventional means even when taken in a much smaller amount than the latter.
To prepare the conventional means, coating of an aqueous enteric coating film over powder or granules :: `
of sodium polyacrylate is necessary. However, such coating is very complicated. For instance, a material of the aqueous enteric Foating film, such as hYdroxYProPYlmethyl cellulose :
.
`' ~ - ' - ' '' ' :, ' '. ' -- . .
2~Gti~S
acetate succinate, may be dissolved only ln a highly inflammable and toxic solvent such as acetone; and the material is sprayed and dried over granules of sodium polyacrylate. Such treatment needs much expensive facilities and manY steps to the result that the cost of the coated granules is inevitably high.
Contrary to this, the drink means of the present invention may well be prepared only by adding sodium polyacrYlate into an acidic aqueous liquid followed by blending them. Thus, it may be prepared extremelY easily at a low cost.
Next, the present invention will be explained in more detail by way of the following examples, which, however, are not intended to restrict the scope of the present invention.
EXAMPLE
Pre~aration of Drink Means:
1000 mg of ascorbic acid was dissolved in 100 ml of a so-called sports drink-like toned aqueous liquid as prepared by adding an electrolyte to water along with some flavorings, to yield an acidic aqueous liquid. This had an aciditY of pH 2.8 and gave an acidic taste.
0.05 g of sodium polyacrylate was dissolved in 100 ml of the liquid to prepare a drink means.
Before and after addition of sodium polyacrylate, the liquid had no noticeable change in the viscosity and the fluidity. (The viscosity was about 0.02 poise a-t 20~C.) ~ .
' '' , ' , ~3(jv~
Test of_Drlnk Means:
The conditions of testing the drink means thus prepared are as follows:
- 14 - ~ J J ~ ~
a~
o a~
J ~
C~ O O O 9 O ~ _ o O ~ ~ p, ~, ~, p, O O o~
O O O O O O
S
O
~1 ~11~ 5 ~ ~ ~1 ~
C~ O O O O O O
~
O q~
C~ O
~1 ~
,~ _ ~:: Ot--111 N ~ u) ~ . . . .
O ~
S--~0 ~ OCO OC`~ O C~
O ~~1 ~ ~I Q) ~( X ~ 0 ~ 0 ~
e ~
c~ v U~ tO
q~
U~ O U~
--I ¢o~ C) ~ r~
C~
o h 1~ t ~i Test Period: Four months from July to October, 1991 How to take the drink means:
They took lOO ml of the drink means each at their lunch and supper meals (corresponding to about 0.1 g/day of-sodium polyacrylate).
The contents of their meals were not specifically defined and they continued their own ordinarY dietary habits during the test.
How to obtain the test data:
All the panelists were subjected to general blood examination and biochemical examination of about 40 items, before the test and at every one month after initiation of the test, whereupon the variation of the condition of each of them was checked continuously.
From the test results, noticeable depression of the leucine aminopeptidase, choline esterase, triglyceride, whole cholesterol and beta-lipoprotein in the serum was admitted in all the panelists. The test data are shown in Fig. 1 to Fig. 5, in which each line graph indicates the variation of the tested item of each panelist tested. As is noted therefrom, depresslon of all the tested components in the serum is significant in every panelist. Thus. the effect of taking the drink means was demonstrated by the test.
Naturally, the total cholesterol is to gradually lower in three~months to a half year or to one year. In the present test, depression of the value was obvious in four (A, B, D, F) of all the six panelists. The effect of the drlnk means was veriiied also in this point.
~:
' . .
:, .
t~
The variation of the weigh~ of each panellst was as follows:
Variation of Weight:
During the test, the condition of each panelist of evacuating the bowels (the number of evacuating the bowels, the amount of the discharged feces, the appearance of the discharged feces, and the condition in evacuating the bowels, etc.) as well as the variation of the subjective symptoms of each panelist during the test period of four months of taking the drink means of the example were recorded every day. Before the test, all the panelists were in the habit of being constipated. From 3 days to one week after initiation of the test of taking the drink means, all became to evacuate the bowels once to three times a day. Both the solidness of lS the discharged feces and the condition thereof were good.
In addition, it was also observed that the color of the discharged feces changed to a clear bile color in every panelist. This means that the drink means of the present invention coagulated the bile and bile acid in the tested panelist to discharge them out of the body. Bile acid is formed essentially from the blood lipids and is again absorbed in the jejunum. Due to inhibition of the absorption of the bile acid in the jejunum, the metabolism of fats in the body is thereby promoted. In this point, the drink means of the present invention is noted to have still other effects of palliating hyperlipemia and of palliating hypohepatia.
Claims (5)
1. An inhibitor for absorption of digested and decomposed products of food and drink, comprising an acidic aqueous liquid containing sodium polyacrylate.
2. The inhibitor for absorption of digested and decomposed products of food and drink as claimed in claim 1, which has a pH value of 5 or less.
3. The inhibitor for absorption of digested and decomposed products of food and drink as claimed in claim 2, which has a pH value of from 2.5 to 3.5.
4. The inhibitor for absorption of digested and decomposed products of food and drink as claimed in claim 1, which has a viscosity of from 0.3 to 0.6 poise.
5. The inhibitor for absorption of digested and decomposed products of food and drink as claimed in claim 1, in which the acidic aqueous liquid is one selected from an aqueous ascorbic acid solution, an aqueous citric acid solution, an aqueous acetic acid solution, juices of citrus fruits and combination of them.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3359568A JPH05186357A (en) | 1991-12-31 | 1991-12-31 | Absorption-inhibitory means for digested product of food/ beverage |
JP359568/1991 | 1991-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2086566A1 true CA2086566A1 (en) | 1993-07-01 |
Family
ID=18465171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002086566A Abandoned CA2086566A1 (en) | 1991-12-31 | 1992-12-31 | Inhibitor for absorption of digested and decomposed products of food and drink |
Country Status (7)
Country | Link |
---|---|
JP (1) | JPH05186357A (en) |
AU (1) | AU3045592A (en) |
CA (1) | CA2086566A1 (en) |
CH (1) | CH684740A5 (en) |
DE (1) | DE4244588A1 (en) |
FR (1) | FR2685611B1 (en) |
GB (1) | GB2262888B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
ATE349214T1 (en) | 2001-09-08 | 2007-01-15 | Astrazeneca Ab | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH AN INHIBITING EFFECT ON ACID TRANSPORT IN THE BILITIES FOR THE TREATMENT OF HYPERLIPIDAEMIA |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) * | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
AU2008202120B2 (en) * | 2003-04-05 | 2009-12-17 | Albireo Ab | Use of an IBAT inhibitor for the treatment of prophylaxis of constipation |
KR101890959B1 (en) | 2010-11-08 | 2018-08-22 | 알비레오 에이비 | Ibat inhibitors for the treatment of liver diseases |
JO3301B1 (en) | 2013-04-26 | 2018-09-16 | Albireo Ab | Crystal modifications of elobixibat |
CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
JOP20200297A1 (en) | 2018-06-20 | 2020-11-22 | Albireo Ab | Crystal modifications of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
DK4069360T3 (en) | 2019-12-04 | 2024-02-26 | Albireo Ab | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CN114786772B (en) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | Benzothiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
CN116157389A (en) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | Benzothiazepine compounds and their use as bile acid modulators |
CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2221139B1 (en) * | 1973-03-13 | 1978-03-24 | Nippon Kayaku Kk | |
DE3307816A1 (en) * | 1983-03-02 | 1984-09-06 | Schering AG, 1000 Berlin und 4709 Bergkamen | PROSTAGLANDINE-CONTAINING PHARMACEUTICAL PREPARATION AND ITS PRODUCTION |
GB8419245D0 (en) * | 1984-07-27 | 1984-08-30 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
JPS61172815A (en) * | 1985-01-28 | 1986-08-04 | Toshiyuki Nakajima | Lubricant |
GB8817015D0 (en) * | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
GB8910076D0 (en) * | 1989-05-03 | 1989-06-21 | Thackray C F Ltd | Sterilisable lubricant |
JPH03120227A (en) * | 1989-10-02 | 1991-05-22 | Shigeo Ochi | Agent for absorbing and suppressing digested and degraded product of food and drink |
-
1991
- 1991-12-31 JP JP3359568A patent/JPH05186357A/en active Pending
-
1992
- 1992-12-30 CH CH3987/92A patent/CH684740A5/en not_active IP Right Cessation
- 1992-12-30 FR FR929215947A patent/FR2685611B1/en not_active Expired - Fee Related
- 1992-12-30 GB GB9227128A patent/GB2262888B/en not_active Expired - Fee Related
- 1992-12-30 AU AU30455/92A patent/AU3045592A/en not_active Abandoned
- 1992-12-31 CA CA002086566A patent/CA2086566A1/en not_active Abandoned
- 1992-12-31 DE DE4244588A patent/DE4244588A1/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
FR2685611A1 (en) | 1993-07-02 |
FR2685611B1 (en) | 1994-06-10 |
JPH05186357A (en) | 1993-07-27 |
GB2262888B (en) | 1996-07-24 |
AU3045592A (en) | 1993-07-08 |
GB2262888A (en) | 1993-07-07 |
GB9227128D0 (en) | 1993-02-24 |
DE4244588A1 (en) | 1993-07-15 |
CH684740A5 (en) | 1994-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2086566A1 (en) | Inhibitor for absorption of digested and decomposed products of food and drink | |
DE60002331T3 (en) | COMPOSITIONS FOR CREATING AND MAINTAINING ENERGY AND MENTAL WAXES | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
CN101180048B (en) | Amino acid composition for improving glucose tolerance | |
JP4095115B2 (en) | Aloe vera extract, method for producing aloe vera extract, hyperglycemia improving agent | |
EP2448591B1 (en) | Composition and method for reducing food intake | |
DE69630694T2 (en) | NEUTRALIZATION OF ACID FOOD AND MEDICINAL PRODUCTS | |
DE2621000A1 (en) | NUTRITIONAL DEFICIENCY PREVENTION COMPOSITION | |
US20110177175A1 (en) | Dietary fiber compositions | |
US10449165B2 (en) | Foods, systems, methods, and kits for providing electrolyte replacement | |
US20040096527A1 (en) | Compositions for lowering serum cholesterol level | |
JP2006028051A (en) | Ameliorant for exhausted feeling at time of rising, composition for ameliorating exhausted feeling at time of rising, and food and beverage for ameliorating exhausted feeling at time of rising, containing them | |
JP3634721B2 (en) | Preventive or therapeutic agent for hyperlipidemia | |
CN101730475A (en) | Body-weight maintenance and body composition | |
US4273794A (en) | Composition containing honey | |
JPH0919276A (en) | Healthy beauty beverage | |
US6599522B2 (en) | Triglyceride reducing agent | |
DE602004010741T2 (en) | Use of monosaccharide phosphates to improve intestinal function | |
JP2003095941A (en) | Sugar digestion enzyme inhibitor, hyperglycemia inhibitor, therapeutic or prophylactic agent for obesity, therapeutic or prophylactic agent for diabetes, and healthy food and drink | |
JP2011241216A (en) | Food containing nemacystus decipiens-derived fucoidan | |
Rathore et al. | Clinical study to evaluate the efficacy of Indukantam Ghritam (SY) in the management of Balshosha WSR to PEM (Protein Energy Malnutrition) | |
KR20230101959A (en) | Powder For Candyfloss Containing Functional Food Additive | |
TW200533300A (en) | Composition for inhibting dietary lipid absorption | |
Editorial Submission | From the Editors... Answering Consumer Questions on Nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |